In a global Phase 1 dose-escalation study (NCT05892718), HCB101 monotherapy demonstrated a favorable safety profile, high CD47 receptor occupancy (saturating RO levels across multiple doses), and ...

Target engagement increased in a dose-dependent manner, with CD47 receptor occupancy ranging up to 100% at the highest doses evaluated. ACC Abstract Details ...

In preclinical models of atherosclerosis, CD47 receptor occupancy of 6-26% correlated with meaningful reductions in aortic plaque burden relative to controls.

In preclinical models of atherosclerosis, CD47 receptor occupancy of 6-26% correlated with meaningful reductions in aortic plaque burden relative to controls.

Fosun Pharma subsidiary Henlius Biotech is paying $10 million upfront for regional rights to HanchorBio’s phase 2 CD47 blocker. In return for the rights to develop and commercialize the ...

There are currently no approved drugs that target the CD47 receptor, a protein embedded in cell membranes that instructs macrophages not to destroy the cell. Cancer cells take advantage of CD47 to ...

Summary ALX Oncology's main focus is the CD47 blocker evorpacept, which has shown encouraging results in combination with other therapies for various cancers. The company has a strong financial ...

In a global Phase 1 dose-escalation study (NCT05892718), HCB101 monotherapy demonstrated a favorable safety profile, high CD47 receptor occupancy (saturating RO levels across multiple doses), and ...

In preclinical models of atherosclerosis, CD47 receptor occupancy of 6-26% correlated with meaningful reductions in aortic plaque burden relative to controls.

In a global Phase 1 dose-escalation study (NCT05892718), HCB101 monotherapy demonstrated a favorable safety profile, high CD47 receptor occupancy (saturating RO levels across multiple doses), and ...